DE69310065D1 - Verwendung von 2-(3,4-Dimethoxycinnamoyl)aminobenzoesäure zur Herstellung eines Arzeimittels zur Behandlung der Restenose - Google Patents
Verwendung von 2-(3,4-Dimethoxycinnamoyl)aminobenzoesäure zur Herstellung eines Arzeimittels zur Behandlung der RestenoseInfo
- Publication number
- DE69310065D1 DE69310065D1 DE69310065T DE69310065T DE69310065D1 DE 69310065 D1 DE69310065 D1 DE 69310065D1 DE 69310065 T DE69310065 T DE 69310065T DE 69310065 T DE69310065 T DE 69310065T DE 69310065 D1 DE69310065 D1 DE 69310065D1
- Authority
- DE
- Germany
- Prior art keywords
- dimethoxycinnamoyl
- restenosis
- medicament
- manufacture
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4288086A JP2617407B2 (ja) | 1992-09-14 | 1992-09-14 | 血管内膜細胞過剰増殖疾患の予防および治療剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69310065D1 true DE69310065D1 (de) | 1997-05-28 |
DE69310065T2 DE69310065T2 (de) | 1997-11-20 |
Family
ID=17725612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69310065T Expired - Fee Related DE69310065T2 (de) | 1992-09-14 | 1993-08-26 | Verwendung von 2-(3,4-Dimethoxycinnamoyl)aminobenzoesäure zur Herstellung eines Arzeimittels zur Behandlung der Restenose |
Country Status (7)
Country | Link |
---|---|
US (1) | US5385935A (de) |
EP (1) | EP0588518B1 (de) |
JP (1) | JP2617407B2 (de) |
KR (1) | KR100252410B1 (de) |
CA (1) | CA2106172C (de) |
DE (1) | DE69310065T2 (de) |
HK (1) | HK1005425A1 (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US5770609A (en) | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6306421B1 (en) | 1992-09-25 | 2001-10-23 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6395494B1 (en) * | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6663881B2 (en) | 1993-01-28 | 2003-12-16 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5595722A (en) * | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
JPH08510451A (ja) * | 1993-05-13 | 1996-11-05 | ネオルックス コーポレイション | 異常増殖性平滑筋細胞に関連した病因の予防及び治療 |
US5824644A (en) * | 1994-07-07 | 1998-10-20 | G. D. Searle & Co. | Method of attenuating arterial stenosis |
US20030083733A1 (en) * | 1997-10-10 | 2003-05-01 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US20020091433A1 (en) * | 1995-04-19 | 2002-07-11 | Ni Ding | Drug release coated stent |
US5837313A (en) * | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US6099562A (en) * | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
ATE377418T1 (de) * | 1995-06-07 | 2007-11-15 | Poniard Pharmaceuticals Inc | Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen |
US7611533B2 (en) * | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
CN1211182A (zh) | 1996-02-15 | 1999-03-17 | 橘生药品工业株式会社 | 新血管形成抑制剂 |
JPH09278653A (ja) * | 1996-04-05 | 1997-10-28 | Santen Pharmaceut Co Ltd | 網膜疾患治療剤 |
US6019104A (en) * | 1996-12-30 | 2000-02-01 | Kissei Pharmaceutical Co., Ltd. | Method for the treatment or prevention of restenosis associated with coronary intervention |
CN1118279C (zh) * | 1997-02-14 | 2003-08-20 | 橘生药品工业株式会社 | 曲尼司特用于制备抑制翼状胬肉发展及其术后复发的药物 |
US6511477B2 (en) * | 1997-03-13 | 2003-01-28 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
RU2207852C2 (ru) * | 1997-04-18 | 2003-07-10 | Киссеи Фармасьютикал Ко., Лтд. | Средства для предотвращения или лечения болезней, связанных с чрезмерной пролиферацией эпителиальных пигментных клеток сетчатки |
JP4583597B2 (ja) * | 1998-05-05 | 2010-11-17 | ボストン サイエンティフィック リミテッド | 末端が滑らかなステント |
CN1345237A (zh) * | 1999-02-03 | 2002-04-17 | 史密丝克莱恩比彻姆公司 | 预防或降低与冠脉介入有关的心血管事件的方法 |
AR022475A1 (es) * | 1999-02-03 | 2002-09-04 | Smithkline Beecham Corp | Metodo para la prevencion o reduccion de eventos cardiovasculares asociados con intervencion coronaria. |
ES2250154T3 (es) | 1999-07-16 | 2006-04-16 | Kissei Pharmaceutical Co., Ltd. | Agentes que inhiben las reacciones de rechazo cronico despues de un transplante de organo. |
US20060216313A1 (en) * | 1999-08-10 | 2006-09-28 | Allergan, Inc. | Methods for treating a stricture with a botulinum toxin |
US6767544B2 (en) | 2002-04-01 | 2004-07-27 | Allergan, Inc. | Methods for treating cardiovascular diseases with botulinum toxin |
WO2001062241A1 (en) * | 2000-02-23 | 2001-08-30 | Smithkline Beecham Corporation | Method for the prevention or reduction of vascular access dysfunction |
US6613083B2 (en) * | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
WO2004002367A1 (fr) * | 2002-06-27 | 2004-01-08 | Microport Medical (Shanghai) Co., Ltd. | Stent eluant des medicaments |
US20080306126A1 (en) * | 2004-01-05 | 2008-12-11 | Fonseca Vivian A | Peroxisome proliferator activated receptor treatment of hyperhomocysteinemia and its complications |
US7473738B2 (en) * | 2004-09-30 | 2009-01-06 | Johnson & Johnson Vision Care, Inc. | Lactam polymer derivatives |
US8668703B2 (en) * | 2006-12-01 | 2014-03-11 | Wake Forest University Health Sciences | Medical devices incorporating collagen inhibitors |
EP2455077B1 (de) | 2009-06-17 | 2014-06-11 | National University Corporation Kumamoto University | Prophylaxe- und/oder behandlungsmittel für dysmenorrhoe |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5640710B2 (de) * | 1973-01-18 | 1981-09-22 | ||
US4070484A (en) * | 1973-01-18 | 1978-01-24 | Kissei Pharmaceutical Co., Ltd. | Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same |
US4337270A (en) * | 1980-05-21 | 1982-06-29 | Hisamitsu Pharmaceutical Co., Inc. | Novel anthranilic acid derivatives |
-
1992
- 1992-09-14 JP JP4288086A patent/JP2617407B2/ja not_active Expired - Fee Related
-
1993
- 1993-08-26 EP EP93306787A patent/EP0588518B1/de not_active Expired - Lifetime
- 1993-08-26 DE DE69310065T patent/DE69310065T2/de not_active Expired - Fee Related
- 1993-09-07 US US08/116,701 patent/US5385935A/en not_active Expired - Lifetime
- 1993-09-13 KR KR1019930018347A patent/KR100252410B1/ko not_active IP Right Cessation
- 1993-09-14 CA CA002106172A patent/CA2106172C/en not_active Expired - Fee Related
-
1998
- 1998-05-27 HK HK98104564A patent/HK1005425A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1005425A1 (en) | 1999-01-08 |
JP2617407B2 (ja) | 1997-06-04 |
CA2106172C (en) | 2001-01-02 |
DE69310065T2 (de) | 1997-11-20 |
CA2106172A1 (en) | 1994-03-15 |
KR100252410B1 (ko) | 2000-05-01 |
US5385935A (en) | 1995-01-31 |
KR940006578A (ko) | 1994-04-25 |
EP0588518A1 (de) | 1994-03-23 |
JPH06135829A (ja) | 1994-05-17 |
EP0588518B1 (de) | 1997-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69310065T2 (de) | Verwendung von 2-(3,4-Dimethoxycinnamoyl)aminobenzoesäure zur Herstellung eines Arzeimittels zur Behandlung der Restenose | |
ATE206919T1 (de) | Verwendung des wirkstoffs flupirtin zur herstellung eines arzneimittels zur bekämpfung von muskelverspannungen | |
DE69705877D1 (de) | Verwendung von Anionenaustauscherharzen zur Herstellung eines Arzneimittels zur Behandlung der Hyperphosphatemie | |
DE3785740T2 (de) | Verwendung von Carboxamid-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung der Hyperlipämie. | |
ATE137965T1 (de) | Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege | |
ATE206926T1 (de) | Verwendung eines phosphorsäurediesters zur herstellung eines arzneimittels zur behandlung von akne | |
DE69637449D1 (de) | Verwendung von alpha-hydroxysäuren zur herstellung eines arzneimittels für die behandlung von entzündungen | |
ATE246518T1 (de) | Egr-1 zur herstellung eines medikamentes zur behandlung von wunden | |
DE69423577D1 (de) | Verwendung von Oenothein B zur Herstellung eines Medikaments zur Behandlung der durch Hyperandrogenität bedingte Störungen. | |
DE69232911T2 (de) | Verwendung eines polyhydroxybenzamids oder dessen Derivat zur Herstellung eines Medikaments für die Behandlung von viralen Infektionen | |
DE50010234D1 (de) | Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz | |
DE69005978T2 (de) | Verwendung von Actinonin zur Herstellung eines Medikamentes zur Inhibierung der Angiogenese. | |
DE69007065D1 (de) | Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten. | |
ATE183088T1 (de) | Arzneimittel zur behandlung von hauterkrankungen | |
DE68905657T2 (de) | Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen. | |
DE69300037D1 (de) | Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria. | |
HUP9904029A3 (en) | Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis | |
DE3483944D1 (de) | Verwendung von selektiv peripheren dopamin-antagonisten zur herstellung eines arzneimittels zur topischen behandlung von okularer hypertension. | |
DE69620786T2 (de) | Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie | |
DE69610045T2 (de) | Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen | |
DE50012667D1 (de) | Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen | |
ATE192650T1 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit | |
DE69632117D1 (de) | Verwendung von 8,9-Dehydroestron zur Herstellung eines Arzneimittels zur Behandlung von durch freie Radikale verursachte Krankheiten | |
DE69228235T2 (de) | Verwendung eines Mittels zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankung | |
DE69404370D1 (de) | Gelatinase A zur Behandlung von der Alzheimerschen Krankheit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |